Alterity Therapeutics Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Alterity Therapeutics Limited generated cash of -$12,605,824, which is more than the previous year. Cash used in financing activities reached the amount of $9,216,292 last year. Net change in cash is therefore -$3,134,898.
Cash Flow
| 2015 | -10.87M | -182.83K | 6.84M |
|---|---|---|---|
| 2016 | -7.41M | -833 | 902.79K |
| 2017 | -5.86M | -27.91K | -159.56K |
| 2018 | -6.24M | -18.41K | -107.67K |
| 2019 | -13.95M | -7.02K | 12.72M |
| 2020 | -9.43M | -16.74K | 3.98M |
| 2021 | -17.33M | -3K | 36.78M |
| 2022 | -12.33M | -89.14K | 16.30M |
| 2023 | -20.03M | -36.46K | 124.34K |
| 2024 | -12.60M | -5.72K | 9.21M |
ATHE Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 15.77M | 34.80M | 28.11M | 9.19M | 14.39M | 15.23M | 21.88M | 28.59M | 34.90M | 34.16M |
Operating activities | ||||||||||
Net income | -19.12M | -13.80M | -12.84M | -15.30M | -10.05M | -12.33M | -8.26M | -7.54M | -7.72M | -5.88M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 147.52K | 102.26K | 54.21K | 75.36K | 112.42K | 29.69K | 21.79K | 21.32K | 22.81K | 31.58K |
Stock-based compensation expense | 881.95K | 966.57K | 1.50M | 1.88M | 0 | 89.13K | 0 | 24.46K | 0 | 468.83K |
| Deferred income tax benefit | 881.95K | 966.57K | 1.50M | 1.88M | 0 | 89.13K | 0 | 24.46K | 0 | 468.83K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 4.62M | -3.94M | -447.68K | -3.16M | 3.29M | -1.67M | -116.83K | 1.74M | 1.73M | 764.25K |
Inventories | 0 | 2.45M | -2.21M | 0 | 0 | -662.92K | 18.98K | -4.06K | -127.71K | -63.97K |
Accounts payable | 1.10M | -1.56M | 2.60M | 432.90K | -648.57K | 662.92K | 1.16M | -856.13K | -403.44K | -1.20M |
Cash generated by operating activities | -12.60M | -20.03M | -12.33M | -17.33M | -9.43M | -13.95M | -6.24M | -5.86M | -7.41M | -10.87M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -154.07K |
Investments In Property Plant And Equipment | -5.72K | -7.31K | -89.14K | -3K | -16.74K | -7.02K | -62.40K | -27.91K | -2.30K | -28.75K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -5.72K | -36.46K | -89.14K | -3K | -16.74K | -7.02K | -18.41K | -27.91K | -833 | -182.83K |
Financing activities | ||||||||||
Common Stock Issued | 10.14M | 316.67K | 17.17M | 39.23M | 4.36M | 13.08M | -107.67K | -159.56K | 0 | 7.12M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -10.37K | 0 | -34.51K | -58.28K | -89.24K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 9.21M | 124.34K | 16.30M | 36.78M | 3.98M | 12.72M | -107.67K | -159.56K | 902.79K | 6.84M |
Net Change In Cash | -3.13M | -19.03M | 6.69M | 18.91M | -5.20M | -835.65K | -6.64M | -6.70M | -6.31M | 742.55K |
Cash at end of period | 12.63M | 15.77M | 34.80M | 28.11M | 9.19M | 14.39M | 15.23M | 21.88M | 28.59M | 34.90M |
| Data source | Data source | Data source | Data source | Data source |